Ovarian_NN
and_CC
breast_NN
cytotoxic_JJ
T_NN
lymphocytes_NNS
can_MD
recognize_VB
peptides_NNS
from_IN
the_DT
amino_NN
enhancer_NN
of_IN
split_JJ
protein_NN
of_IN
the_DT
Notch_NN
complex_NN
._.

In_IN
this_DT
study_NN
we_PRP
investigated_VBD
recognition_NN
by_IN
ovarian_JJ
tumor_NN
associated_VBN
lymphocyte_NN
-LRB-_-LRB-
OVTAL_NN
-RRB-_-RRB-
,_,
and_CC
breast_NN
tumor_NN
associated_JJ
lymphocytes_NNS
-LRB-_-LRB-
BRTAL_NNS
-RRB-_-RRB-
,_,
of_IN
peptides_NNS
corresponding_VBG
to_TO
the_DT
sequence_NN
125-135_CD
of_IN
the_DT
Aminoenhancer_NN
of_IN
split_JJ
-LRB-_-LRB-
AES_NN
-RRB-_-RRB-
protein_NN
._.

Three_CD
of_IN
these_DT
peptides_NNS
designated_VBN
as_IN
G75_NN
:_:
AES1\/2_NN
-LRB-_-LRB-
128-135_CD
-RRB-_-RRB-
,_,
G60_NN
:_:
AES1\/2_NN
-LRB-_-LRB-
127-137_CD
-RRB-_-RRB-
and_CC
G61_NN
:_:
AES1\/2_NN
-LRB-_-LRB-
125-133_CD
-RRB-_-RRB-
correspond_VBP
to_TO
the_DT
wildtype_JJ
AES_NN
sequence_NN
,_,
while_IN
the_DT
fourth_JJ
G76_NN
:_:
GPLTPLPV_NNP
,_,
AES1\/2_NNP
-LRB-_-LRB-
128-135_CD
-RRB-_-RRB-
corresponds_VBZ
to_TO
a_DT
variant_JJ
sequence_NN
of_IN
the_DT
peptide_NN
G75_NN
with_IN
the_DT
N-terminal_JJ
Leu_NN
substituted_VBN
to_TO
glycine_NN
._.

These_DT
sequences_NNS
were_VBD
chosen_VBN
for_IN
study_NN
because_IN
mass-spectrometric_JJ
analysis_NN
-LRB-_-LRB-
MS_NN
-RRB-_-RRB-
of_IN
a_DT
CTL_NN
active_JJ
HPLC_NN
peptide_NN
fraction_NN
eluted_VBN
from_IN
immunoaffinity_NN
precipitated_JJ
HLA-A2_NN
molecule_NN
,_,
revealed_VBN
:_:
-LRB-_-LRB-
a_LS
-RRB-_-RRB-
the_DT
presence_NN
of_IN
an_DT
ion_NN
with_IN
a_DT
mass-to-charge_JJ
ratio_NN
-LRB-_-LRB-
m\/z_NN
-RRB-_-RRB-
of_IN
793_CD
which_WDT
was_VBD
more_RBR
abundant_JJ
than_IN
other_JJ
ions_NNS
of_IN
similar_JJ
masses_NNS
;_:
-LRB-_-LRB-
b_LS
-RRB-_-RRB-
the_DT
tentatively_RB
reconstituted_VBN
sequence_NN
of_IN
the_DT
ion_NN
793_CD
matched_VBD
the_DT
sequence_NN
of_IN
peptide_NN
G76_NN
._.

We_PRP
found_VBD
that_IN
AES_NN
peptides_NNS
G75_NN
-LRB-_-LRB-
128-135_CD
-RRB-_-RRB-
and_CC
G76_NN
-LRB-_-LRB-
128-135_CD
-RRB-_-RRB-
-LRB-_-LRB-
L128G_NN
-RRB-_-RRB-
reconstituted_VBD
CTL_NN
recognition_NN
at_IN
concentrations_NNS
ranging_VBG
between_IN
200-500_CD
nM_NN
._.

These_DT
concentrations_NNS
are_VBP
lower_JJR
than_IN
concentrations_NNS
reported_VBN
to_TO
activate_VB
effector_NN
function_NN
of_IN
CTL_NN
recognizing_VBG
other_JJ
epithelial_JJ
tumor_NN
Ag_NN
._.

Furthermore_RB
,_,
analysis_NN
with_IN
cloned_VBN
CD8_NN
+_CC
T_NN
cells_NNS
indicated_VBD
that_IN
G75_NN
and_CC
G76_NN
were_VBD
not_RB
cross-reactive_JJ
specificities_NNS
,_,
suggesting_VBG
a_DT
key_JJ
role_NN
for_IN
the_DT
N-terminal_JJ
residues_NNS
of_IN
the_DT
variant_JJ
peptide_NN
in_IN
dictating_JJ
specificities_NNS
._.

Since_IN
the_DT
AES_NN
proteins_NNS
are_VBP
part_NN
of_IN
a_DT
set_NN
of_IN
transcriptional_JJ
repressors_NNS
encoded_VBN
by_IN
the_DT
Enhancer_NN
of_IN
split_JJ
-LCB-_-LRB-
E_NN
-LRB-_-LRB-
spl_NN
-RRB-_-RRB-
-RCB-_-RRB-
genes_NNS
,_,
and_CC
since_IN
these_DT
repressors_NNS
are_VBP
activated_VBN
to_TO
suppress_VB
cell_NN
differentiation_NN
in_IN
response_NN
to_TO
Notch_NN
receptors_NNS
signalling_NN
,_,
the_DT
AES_NN
peptides_NNS
may_MD
represent_VB
a_DT
novel_JJ
class_NN
of_IN
self-antigens_NNS
that_WDT
deserve_VBP
further_JJ
consideration_NN
as_IN
tumor_NN
Ag_NN
in_IN
epithelial_JJ
cancers_NNS
._.

